# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN
- Date: 2026-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review at the midpoint of combination treatment, on the day of cycle 4. **S**

## History of present illness

Ms. Ifill returns on the day of her fourth cycle. Cycles 2 and 3 were given on schedule in the infusion center. Nausea lasts a day or two after each cycle and is controlled with ondansetron two or three times. For about two weeks she has had tingling in her toes that does not affect walking or balance. Her hair has thinned and she wears a wig. She has had no diarrhea, rash, cough, breathlessness or headache. She is tired for two or three days after each cycle and works from home on those days. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Cycle 4 of 6 today; cycles 2 and 3 on schedule |
| Nausea | One or two days after each cycle; controlled |
| Neuropathy | Tingling in the toes for two weeks; no effect on function |
| Immune-related symptoms | None |
| Mood | PHQ-9 5 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for two or three days after each cycle; no fever |
| Gastrointestinal | Positive | Nausea for one or two days after each cycle; no vomiting or diarrhea |
| Neurological | Positive | Tingling in the toes; no weakness or falls; no headache |
| Integumentary | Positive | Hair thinning; no rash or itching |
| Respiratory | Negative | No cough or breathlessness |
| Endocrine | Negative | No heat or cold intolerance; no thirst |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles **S**
- Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 71.8 kg; BMI 26.4 kg/m². All vital signs are synthetic.

Hemoglobin: 10.6 g/dL (low); White cell count: 4.3 10*3/uL; Absolute neutrophil count: 2.1 10*3/uL; Platelets: 196 10*3/uL; Creatinine: 0.81 mg/dL; eGFR (CKD-EPI 2021): 83 mL/min/1.73 m²; Glucose: 97 mg/dL; ALT: 24 U/L; AST: 26 U/L; Total bilirubin: 0.5 mg/dL; Magnesium: 1.8 mg/dL; TSH: 4.8 mIU/L (high); Free T4: 1.1 ng/dL; Cortisol (morning): 12.6 ug/dL; PHQ-9: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.8 g/dL (low) at baseline, 10.6 g/dL (low) at this visit **S**
- White cell count: 6.2 10*3/uL at baseline, 4.3 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 196 10*3/uL at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.81 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 82 mL/min/1.73 m² at baseline, 83 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 97 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 71.8 kg; blood pressure 120/76, pulse 82 |
| Abdomen | Soft, non-tender; no mass |
| Extremities | No leg swelling; calf circumferences unchanged |
| Neurological | Pinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait |
| Skin | Hair thinning; no rash |
| Psychiatric | Engaged and composed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Endometrioid endometrial cancer, stage IIIC2ii, MMRd, on dostarlimab with carboplatin and paclitaxel** (C54.1). Tolerating treatment. Counts allow cycle 4: neutrophils 2.1, platelets 196; hemoglobin 10.6 g/dL, mild anemia from chemotherapy without symptoms. Kidney and liver function are normal; magnesium 1.8 mg/dL. TSH 4.8 is just above range with a normal free T4 of 1.1: an early thyroid change to watch, which needs no treatment now. Morning cortisol 12.6 is normal. **S**
   - Cycle 4 today at full dose.
   - TSH and free T4 before each remaining cycle.
   - CT of the chest, abdomen and pelvis two weeks after cycle 6.
2. **Chemotherapy-induced peripheral neuropathy, grade 1** (G62.0). Grade 1 sensory neuropathy from paclitaxel without functional effect. No medicine prevents it; the paclitaxel dose is reduced if it begins to interfere with daily activities (grade 2) or becomes painful. **S**
   - Continue paclitaxel at full dose with a check before each cycle.
   - Report trouble with buttons, writing or balance, or burning pain.
   - Duloxetine if it becomes painful.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.6 g/dL, white cells 4.3, neutrophils 2.1, platelets 196; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.81 mg/dL, eGFR 83; carboplatin dose unchanged |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 24, AST 26 U/L, bilirubin 0.5 mg/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.8 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 4.8 mIU/L, just above range, with free T4 1.1 ng/dL: watch before each cycle |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 97 mg/dL |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Deferred | 12.6 ug/dL today, normal. A deviation: the baseline cortisol deferred at cycle 1 was not drawn before cycles 2 and 3 either, because the request was not carried into the infusion center's standing orders. No harm resulted: today's value is normal and she has had no symptom of adrenal insufficiency. Corrective action: morning cortisol added to the standing orders before every remaining dose; no earlier values are recorded |
| Examination | Peripheral neuropathy: symptoms and examination | Baseline and before each taxane cycle | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling; calf measurements unchanged |
| Examination | Immune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache) | Each visit on a checkpoint inhibitor | Completed today | None reported; skin and chest normal |
| Imaging | Response imaging | At the end of combination treatment, or sooner for symptoms | Not indicated | Not needed at the midpoint after complete resection, with no symptoms; CT after cycle 6 |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Controlled: nausea one or two days per cycle, no vomiting |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | No reaction in three cycles; same premedication |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 5 |

## Goal progress

- Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation. Outcome by 2026-01-20: Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks. **S**
- Surgical staging within four weeks of diagnosis. Outcome by 2026-02-24: Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation. **S**
- Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 2026-06-30. **S**
- Lynch syndrome tumor screening completed and explained before treatment starts. Outcome by 2026-02-24: MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done. **S**
- Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule. In progress; target 2026-06-30. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses. In progress; target 2026-06-30. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026), National Comprehensive Cancer Network
- Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023), New England Journal of Medicine
- JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (GlaxoSmithKline label)
- Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026), Society of Gynecologic Oncology
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Cycles 5 and 6 every 21 days, with TSH, free T4 and a morning cortisol before each. CT about two weeks after cycle 6, then a review with the result and the first maintenance dose. **S**
- Next scheduled visit 2026-06-30: end of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan. **S**
